

DANMAP 2022

Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark



DANMAP 2022

Editors:

Ana Sofia Ribeiro Duarte
Majda Attauabi
Marianne Sandberg
Mikkel Lindegaard
Ute Wolff Sönksen
Vibe Dalhoff Andersen

DANMAP Steering Committee:

National Food Institute: Frank Møller Aarestrup, Marianne Sandberg
Statens Serum Institut: Anders Rhod Larsen, Ute Wolff Sönksen

External reviewers:

Cecilie Hviid Christiansen
Christian Johann Lerche
Inge Jenny Dahl Knudsen
Jette Nygaard Jensen
Joana Pessoa
Jonas Bredtoft Boel
Malene Plejdrup Hansen

Contact:

Ana Sofia Ribeiro Duarte (asrd@food.dtu.dk)
National Food Institute,
Technical University of Denmark
Kemitorvet, Building 204, DK-2800 Kgs. Lyngby

Ute Wolff Sönksen (uws@ssi.dk)
Diagnostic Infectious Disease Preparedness
Statens Serum Institut
Artillerivej 5, DK-2300 Copenhagen

Layout: Anja Bjarnum, Statens Serum Institut

Photos: Colourbox

Printing: Pekema A/S

DANMAP 2022 - November 2023 - ISSN 1600-2032

Text and tables may be cited and reprinted only with reference to this report:

DANMAP 2022 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. ISSN 1600-2032

The report is available from www.danmap.org

DANMAP 2022

Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark

Table of contents

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------|------------|
| 1. Editorial | 9 |
| 2. Introduction to DANMAP | 11 |
| 2.1 The DANMAP surveillance system | 12 |
| 2.2 Information on demographics and health care system | 14 |
| 2.3 Information on animal population and food production system | 16 |
| 2.4 Registered antimicrobial agents | 16 |
| 3. One Health AMR | 19 |
| 3.1 Introduction | 20 |
| 3.2 Genotypic comparison of ESBL/AmpC-producing <i>E. coli</i> from humans, animals and food | 20 |
| Textbox 3.1 Flankophile: A bioinformatics pipeline for prokaryotic genomic synteny analysis | 23 |
| 4. Antimicrobial consumption in animals | 25 |
| 4.1 Introduction | 27 |
| 4.2 Total antimicrobial consumption in animals | 29 |
| 4.3 Antimicrobial consumption by animal species | 31 |
| Textbox 4.1 No more high dose zinc oxide in veterinary medicinal products | 42 |
| Textbox 4.2 New EU legislation on veterinary medicinal products | 43 |
| Textbox 4.3 Faecal microbiota transplantation for prevention of diarrhoea in pigs | 44 |
| 5. Antimicrobial consumption in humans | 47 |
| 5.1 Introduction | 49 |
| 5.2 Total antimicrobial consumption in the Danish healthcare system | 50 |
| 5.3 Antimicrobial consumption in primary health care | 53 |
| 5.4 Antimicrobial consumption at hospitals | 65 |
| Textbox 5.1 Comparison of antibiotic prescribing for elderly in long-term care facilities and elderly living at home | 74 |
| Textbox 5.2 Sociodemographic characterisation of antibiotic heavy users in the Danish elderly population | 76 |
| Textbox 5.3 Incidence of multiresistant bacteria and consumption of antimicrobial agents in Greenland | 78 |
| Textbox 5.4 Shortage of antibiotics at Community Pharmacies in Denmark | 81 |
| Textbox 5.5 Research Units for General Practice in Denmark | 85 |
| 6. Resistance in zoonotic bacteria | 87 |
| 6.1 Introduction | 89 |
| 6.2 <i>Campylobacter</i> | 89 |
| 6.3 <i>Salmonella</i> | 91 |
| Textbox 6.1 Detection of resistance genes and point mutations in <i>Salmonella</i> and <i>Campylobacter</i> using whole genome sequencing | 95 |
| 7. Resistance in indicator bacteria | 99 |
| 7.1 Introduction | 101 |
| 7.2 Indicator <i>Escherichia coli</i> | 101 |
| 7.3 ESBL/AmpC- and carbapenemase-producing <i>E. coli</i> | 103 |
| 7.4 Indicator Enterococci | 107 |
| Textbox 7.1 Antimicrobial resistance trends in indicator <i>E. coli</i> in Danish pigs, broilers, and cattle 2014 to 2022 | 109 |
| 8. Resistance in human pathogens | 113 |
| 8.1 Introduction | 115 |
| 8.2 Results from MiBa data surveillance | 118 |
| 8.2.1 <i>Escherichia coli</i> | 118 |
| 8.2.2 <i>Klebsiella pneumoniae</i> | 122 |
| 8.2.3 <i>Pseudomonas aeruginosa</i> | 126 |

| | | |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| 8.2.4 | <i>Acinetobacter</i> species | 127 |
| 8.2.5 | Enterococci | 128 |
| 8.3 | Results from the reference laboratories | 130 |
| 8.3.1 | Characterization of ESBL- and pAmpC-producing <i>Escherichia coli</i> from bloodstream infections | 130 |
| 8.3.2 | Carbapenemase-producing organisms (CPO) | 132 |
| 8.3.3 | Vancomycin-resistant/vancomycin-variable enterococci | 137 |
| 8.3.4 | Detection of linezolid-resistant enterococci and linezolid-vancomycin-resistant enterococci | 140 |
| 8.3.5 | <i>Staphylococcus aureus</i> | 141 |
| 8.3.6 | <i>Streptococcus pneumoniae</i> | 146 |
| 8.3.7 | Beta-haemolytic streptococci | 148 |
| 8.3.8 | <i>Neisseria gonorrhoeae</i> | 149 |
| 8.3.9 | <i>Haemophilus influenzae</i> | 153 |
| 8.3.10 | Meningococci | 154 |
| Textbox 8.1 | Dicloxacillin capsules contaminated with CPE in Denmark and Iceland | 158 |
| Textbox 8.2 | Fungaemia epidemiology, resistance rates and human antifungal consumption: a 2021-2022 update | 160 |
| Textbox 8.3 | <i>Mycoplasma genitalium</i> | 163 |
| 9. | Resistance in animal pathogens | 165 |
| 9.1 | Introduction | 167 |
| 9.2 | Temporal trends of AMR in pathogenic bacteria from pigs | 167 |
| 9.3 | WGS-based detection of resistance genes and point mutations | 170 |
| 9.4 | WGS-based prediction of AMR | 173 |
| 9.5 | Conclusions and perspectives | 174 |
| Textbox 9.1 | Antimicrobial resistance in dogs and cats: focus on extended-spectrum cephalosporinase-producing <i>Escherichia coli</i> and their resemblance to human clinical isolates | 175 |
| Textbox 9.2 | Insights into the genetic basis of neomycin resistance in clinical <i>Escherichia coli</i> isolated from pigs | 178 |
| Textbox 9.3 | Assessing the burden of Antimicrobial Resistance and Usage in the Global Burden of Animal Disease programme: the start of the Danish case study | 181 |
| 10. | Materials and methods | 183 |
| 10.1 | General information | 184 |
| 10.2 | Data on antimicrobial consumption in animals | 184 |
| 10.3 | Collection of bacterial isolates from animals and meat | 186 |
| 10.4 | Microbiological methods - isolates from animals and meat | 187 |
| 10.5 | Susceptibility testing - isolates from animals and meat | 188 |
| 10.6 | Whole genome sequencing - isolates from animals and meat | 188 |
| 10.7 | Data handling - isolates from animals and meat | 188 |
| 10.8 | Data on antimicrobial consumption in humans | 191 |
| 10.9 | <i>Salmonella</i> and <i>Campylobacter</i> isolates from humans | 192 |
| 10.10 | <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , <i>Pseudomonas aeruginosa</i> , <i>Acinetobacter</i> species, <i>Enterococcus faecium</i> and <i>Enterococcus faecalis</i> isolates from humans | 193 |
| 10.11 | ESBL-producing bacterial isolates from humans | 193 |
| 10.12 | CPO isolates from humans | 194 |
| 10.13 | VRE isolates from humans | 194 |
| 10.14 | Invasive <i>Streptococcus pneumoniae</i> isolates from humans | 194 |
| 10.15 | Isolates of beta-haemolytic streptococci of groups A, B, C, and G from invasive infections in humans | 195 |
| 10.16 | Invasive <i>Haemophilus influenzae</i> isolates from humans | 196 |
| 10.17 | <i>Staphylococcus aureus</i> including MRSA isolates from humans | 196 |
| 10.18 | Gonococci isolates | 197 |
| 11. | Terminology | 199 |
| | List of abbreviations | 200 |
| | Glossary | 201 |